https://www.live-feeds.com/feed/there-s-an-active-recall-on-thyroid-medicine-nationwideContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/there-s-an-active-recall-on-thyroid-medicine-nationwidehttps://www.live-feeds.com/feed/there-s-an-active-recall-on-thyroid-medicine-nationwide#u54506Wed, 02 Sep 2026 07:10:53 +0000Vitruvias Therapeutics Inc. has issued a voluntary nationwide recall for more than 3,600 bottles of 30 mg Thyroid Tablets, USP. Lab testing indicated the medication is superpotent, meaning the pills may be too strong for patients. The FDA warned that these tablets can cause hyperthyroidism. Affected users must check for Lot No. 504950 to determine if their supply is part of the recall. Patients should contact their healthcare providers regarding potential health risks and next steps for replacement medication.Why it mattersThyroid medication requires precise dosing to maintain hormonal balance https://www.live-feeds.com/feed/there-s-an-active-recall-on-thyroid-medicine-nationwidehttps://www.live-feeds.com/feed/there-s-an-active-recall-on-thyroid-medicine-nationwide#u49386Thu, 27 Aug 2026 01:00:22 +0000Vitruvias Therapeutics Inc. issued a voluntary nationwide recall for one lot of 30 mg Thyroid Tablets, USP, after testing revealed the medication could be "superpotent." The FDA issued an urgent alert warning that these tablets may cause hyperthyroidism in patients. The recall specifically affects Lot No. 504950. Patients using this medication should check their product lot numbers to determine if their supply is affected by the potency issue.Why it mattersThyroid medication regulates metabolism and heart rate. Superpotent doses can trigger hyperthyroidism, a condition where the thyr